Recent News

• 03.11.2025 - DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
• 02.24.2025 - DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors
• 02.20.2025 - DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
• 02.10.2025 - DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
• 12.03.2024 - DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
• 11.13.2024 - DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
• 11.13.2024 - DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Recent Filings

• 03.06.2025 - 8-K Current report
• 02.24.2025 - 3 Initial statement of beneficial ownership of securities
• 02.24.2025 - 8-K Current report
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - EX-99.1 EX-99.1
• 02.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.03.2025 - 4 Statement of changes in beneficial ownership of securities